News

FDA Approves Immunotherapy Duo for Kidney Cancer

The Food and Drug Administration approved the immunotherapy combination of Yervoy (ipilimumab) plus Opdivo (nivolumab) to treat patients with intermediate- or poor-risk advanced renal cell carcinoma in the frontline setting.

Read full article on curetoday.com.